Hematologic cancers in 1987. Chemotherapy and immunotherapy
Fillet, G.; Bury, J.; Beguin, Y.; Duvivier, A.; Hoyoux, C.; Bours, V.
Revue Medicale de Liege 42(10): 496-502
1987
ISSN/ISBN: 0370-629X PMID: 2441448 Document Number: 296458
Document emailed within 1 workday
Related Documents
Bosslet, K.; Schwarz, A.; Steinstraesser, A.; Kuhlmann, L.; Seidel, L.; Schulz, G. 1988: Immunoscintigraphy of colorectal cancers and specific immunotherapy of pancreatic cancers using monoclonal antibodies Wiener Medizinische Wochenschrift 138(11-12): 255-257Sampi, K. 1987: Cancer chemotherapy combined with a calcium antagonist in patients with hematologic malignancies and solid tumors resistant to standard chemotherapy Gan to Kagaku Ryoho. Cancer and ChemoTherapy 14(3 Part 2): 951-955
Mellstedt, H.åk.; Veelken, H. 2005: Active immunotherapy in patients with hematologic and solid neoplasms Onkologie 28(Suppl 4): 4-8
Hoerni, B. 1972: Immunotherapy of digestive cancers Medecine and Chirurgie Digestives 1(1): 29-32
2016: New immunotherapy uses defense cells against hematologic cancer. "Living medicine instead of roentgen rays Pflege Zeitschrift 69(6): 323
Grizzi, F.; Di Ieva, A. 2013: Rethinking immunotherapy for brain cancers in the light of cancer complexity Indian Journal of Medical Research 137(5): 871-873
Koda, K.; Glassy, M.C.; McKnight, M.E.; Yasutomi, J.; Saito, N.; Dan, M.; Nakajima, N. 2001: Immunotherapy for recurrent colorectal cancers with human monoclonal antibody SK-1 Anticancer Research 21(1b): 621-627
Gastineau, D.A.; Hoagland, H.C. 1992: Hematologic effects of chemotherapy Seminars in Oncology 19(5): 543-550
Riera, L.; Koziner, B. 2000: Donor lymphocyte infusions as adoptive immunotherapy in patients with relapsed hematologic neoplasms post-allogenic transplant of hematopoietic progenitor cells Medicina 60(2): 259-269
Kanai, T.; Monden, M.; Takeda, T.; Gotoh, M.; Sakon, M.; Umeshita, K.; Hasuike, Y.; Sakita, I.; Nakano, H.; Yoshida, T. 1993: Adoptive immunotherapy in patients with multiple hepatic cancers using lymphokine activated killer cells (LAK) and interleukin-2 Gan to Kagaku Ryoho. Cancer and ChemoTherapy 20(11): 1457-1460
Cardinali, G. 1979: Chemotherapy and immunotherapy of pulmonary cancer Minerva Medica 70(3): 273-282
el-Azzouni, M.Z.; Boulos, L.M. 1992: Heterophyids: experimental chemotherapy and immunotherapy Journal of the Egyptian Society of Parasitology 22(2): 381-389
Tomíska, M.; Dastych, M.; Dolezalová, J.; Vorlícek, J. 1997: The effect of chemotherapy on energy and nitrogen balance in patients with hematologic neoplasms Vnitrni Lekarstvi 43(1): 18-24
Brightwell, R.; Eng, K.; Lele, S. 2017: Use of hematologic biomarkers during chemotherapy predicts survival in ovarian cancer patients European Journal of Gynaecological Oncology 38(3): 378-381
Knerich, R.; Adinolfi, D.; Silvani, V.; Robustelli della Cuna, G.; Spanu, G.; Preti, P.; Rodriguez y Baena, R. 1984: Chemotherapy and immunotherapy of intracranial malignant gliomas Minerva Medica 75(21): 1333-1340
Amiel, J.L. 1977: Chemotherapy and immunotherapy of cancer. Current advances Semaine des Hopitaux. Therapeutique 53(9): 473-474
Panettiere, F.J.; Constanzi, J.J. 1979: Advances in the chemotherapy and immunotherapy of lung cancer Texas Medicine 75(2): 95-97
Naito, K. 2002: Chemotherapy for prostate cancers Nihon Rinsho. Japanese Journal of Clinical Medicine 60(Suppl 11): 205-210
Lièvre, A.; Mitry, E. 2003: Chemotherapy for colorectal cancers Journal de Chirurgie 140(1): 52-55
Seitz, J.F. 1993: Chemotherapy in cancers of the colon Gastroenterologie Clinique et Biologique 17(2 Part 3): T2-12